Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decipher LabsBOM:524752 -3.02%57 EBITDA Margin % is 6.28% as of Mar. 2026, which is 216% above its 10-year median of 1.99. GuruFocus rates BOM:524752 with a GF Score™ of 57/100 and a GF Value™ of ₹6.33 (Fairly Valued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Decipher Labs ranks worse than 84.78% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Decipher Labs's EBITDA for the
three
months ended in Mar. 2026 was ₹2.3 Mil. Decipher Labs's Revenue for the
three
months ended in Mar. 2026 was ₹36.0 Mil. Therefore, Decipher Labs's EBITDA margin for the quarter that ended in Mar. 2026 was 6.28%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Decipher Labs EBITDA Margin % Related Terms
Decipher Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Decipher Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524752 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Decipher Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decipher Labs EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Decipher Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Decipher Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Decipher Labs (BOM:524752) has a EBITDA Margin % of 6.28% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Decipher Labs and its competitors. This is 216% above median its historical median of 1.99. According to the industry distribution chart, Decipher Labs ranks #813 out of 959 companies in the Drug Manufacturers industry, placing it in the top 84.8%.
Is Decipher Labs' EBITDA Margin % too high?
Decipher Labs' current EBITDA Margin % of 6.28% is 216% above median its 10-year median of 1.99. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Decipher Labs' value of 6.28% is 49.9% below this industry median. Based on the distribution chart, Decipher Labs ranks #813 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Decipher Labs has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Decipher Labs' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Decipher Labs ranks #813 out of 959 companies for EBITDA Margin %. This places Decipher Labs in the lower half of its industry. The industry median EBITDA Margin % is 12.54. Decipher Labs' value of 6.28% is 49.9% below this benchmark. While the company's 10-year median is 1.99 vs. the industry median of 12.54, Decipher Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Decipher Labs's current EBITDA Margin % of 6.28% is 49.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Decipher Labs and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decipher Labs's current EBITDA Margin % is 6.28%, which is 216% above median its own 10-year median of 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decipher Labs stock overvalued right now?
Based on GuruFocus' analysis, Decipher Labs (BOM:524752) is currently considered Fairly Valued. The stock's GF Value™ is ₹6.33, compared to a current price of ₹6.10 — trading 3.6% below its estimated fair value. The current EBITDA Margin % is 6.28%, which is 216% above median its 10-year median of 1.99 and 49.9% below the Drug Manufacturers industry median of 12.54. Decipher Labs' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Decipher Labs (BOM:524752), the current EBITDA Margin % is 6.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Decipher Labs (BOM:524752) Overvalued in 2026?
Based on GuruFocus' analysis, Decipher Labs stock appears to be undervalued.
The current stock price of ₹6.10 is trading 3.6% below its estimated GF Value™ of ₹6.33.
GuruFocus considers Decipher Labs to be Fairly Valued.
Key valuation signals for BOM:524752:
EBITDA Margin %: 6.28% (216% above median its 10-year median of 1.99)
GF Value™: ₹6.33 vs. price of ₹6.10 (3.6% below fair value)
Industry Position: 49.9% below the Drug Manufacturers median (#813 of 959)
No single metric tells the full story. See the BOM:524752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Decipher Labs Ltd deals in the trading and manufacturing of Pharmaceutical drugs and allied products and services, and also offers services and key solutions in the Information Technology industry. It is involved in the manufacturing and marketing of its branded pharmaceutical products, and also provides drug development and manufacturing services to various formulators, manufacturers, and Research and Development agencies for their bulk needs. The group's IT Consultancy offerings include Technology Integration and Systems Consulting, Software Development Consulting, and Management of IT projects. Its reportable operating segments are: Pharmaceutical, which generates the maximum revenue, and IT Consultancy Services. Geographically, the group derives its key revenue from India.
57GF Score
Get the complete analysis for BOM:524752
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524752 has been successfully added to your 
